$RUBY News
Last published 4y ago
- 4y agoRUBYRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership ChangesGlobeNewswireDannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc.
- 4y agoDNLIEVLOFHTXMCRB+4Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery PlatformPR NewswireDr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology
- 4y agoDNLIEVLOFHTXMCRB+4Cellarity Announces Close of $121 Million Series C FinancingBusiness WireCellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to
- 4y agoRUBYRubius Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and aut
- 4y agoRUBYRubius Therapeutics Announces Strategic UpdateGlobeNewswireCompany to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of R
- 4y agoRUBYRubius Therapeutics to Provide Strategic UpdateGlobeNewswireCAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red C
- 4y agoDNLIEVLOFHTXMCRB+4Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell BehaviorBusiness WireThe dataset will be publicly available for a Kaggle competition presented at NeurIPS 2022 hosted by Open Problems in Single-Cell Analysis in collaboration with Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, Yale University, and Helmholtz Munich
- 4y agoDNLIEVLOFHTXMCRB+4Senda Biosciences Announces Close of $123 Million Series C FinancingPR NewswireCAMBRIDGE, Mass., Aug. 16, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the completion of a $123 million Series C financing, bringing its total fu
- 4y agoRUBYRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireNew Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H'22 from Phase 1 Arm of RTX-240 + Pembrolizumab in Advanced Solid Tumor
- 4y agoRUBYRubius Therapeutics to Announce Second Quarter 2022 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 4y agoRUBYHotSpot Therapeutics Appoints Jose Carmona to Board of DirectorsPR NewswireBOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment
- 4y agoRUBYRubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 4y agoRUBYRubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual MeetingGlobeNewswirePrevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression Findings Potentially Translatable to Multiple T Cell-Mediated Autoimm
- 4y agoDNLIEVLOFHTXMCRB+4Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive OfficerBusiness WireFlagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined Tessera as Chief Executive Officer. Dr. Severino, wh
- 4y agoRUBYRubius Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 4y agoRUBYRubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual MeetingGlobeNewswireCAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell
- 4y agoDNLIEVLOFHTXMCRB+4Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New MedicinesBusiness WireThe Company's ProFoundry™ Platform has to date identified tens of thousands of previously undiscovered proteins that represent a vastly expanded number of therapeutic targets Flagship commits $75 million to enable the continued expansion of the
- 4y agoRUBYRubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cel
- 4y agoRUBYRubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswirePresented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease Expanded Ongoing Phase 1 Arm of RTX-240 + Pembr
- 4y agoRUBYRubius Therapeutics to Announce First Quarter 2022 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red C
- 4y agoAXLACDAKDNLIEVLO+7Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING PlatformBusiness WireLatest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine
- 4y agoAXLACDAKDNLIEVLO+7Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of AlltrnaPR NewswireWerner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team w
- 4y agoRUBYRubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable TolerabilityGlobeNewswireBest Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Exp
- 4y agoRUBYRubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ETGlobeNewswireCAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red C
- 4y agoRUBYRubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual MeetingGlobeNewswireUpdated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April 12, 2022, from 9:00 a.m. – 12:30 p.m. ET Managem
- 4y agoAXLACDAKDNLIEVLO+8Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory AffairsPR NewswireCAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pa
- 4y agoRUBYRubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireFirst Patient Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with Certain Advanced Solid Tumors in January 2022Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors Continues with No Dose-Limiting Toxicities Observed to Date and
- 4y agoAXLACDAKDNLIEVLO+7INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTPR NewswireCAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental chall
- 4y agoRUBYRubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 4y agoAXLACDAKDNLIEVLO+8Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New MedicinesBusiness WireCompany increases industry expertise with the appointments of Laurens Kruidenier, Ph.D., as Chief Scientific Officer; Anna O'Driscoll as Chief People Officer, and Parul Doshi as Senior Vice President, Head of Data and Software Engineering Cellarity,
- 4y agoRUBYRubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022GlobeNewswireCAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 4y agoAXLACDAKDNLIEVLO+8Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform BiologyPR NewswireCAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental StrategyPR NewswireCAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental St
- 4y agoRUBYRubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid TumorsGlobeNewswireCAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 4y agoRUBYRubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireContinuing Dose Escalation in Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response with Clinical Results Expected in Q1'22 Initial Clinical Results Expected
- 4y agoRUBYRubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 4y agoRUBYRubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline DayGlobeNewswireHighly Versatile and Programmable RED PLATFORM Enables Multiple Modalities to Target Different Immune Pathways Across a Range of Diseases Demonstrated Tolerance Induction with Bystander Suppression in Type 1 Diabetes Preclinical Program with Findings
- 4y agoAXLACDAKDNLIEVLO+9Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of DirectorsBusiness WireEstepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity
- 4y agoRUBYRubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business NewsGlobeNewswireCAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cel
- 4y agoRUBYRubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021GlobeNewswireCAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cel
- 4y agoRUBYRubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cel
- 4y agoAXLACDAKDNLIEVLO+8Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation PlatformBusiness Wire- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics - New capital will enable the company to evolve its technology platform, rapidly sc
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate DevelopmentPR NewswireCAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development. In this
- 5y agoRUBYRubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer's Annual MeetingGlobeNewswireCAMBRIDGE Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell
- 5y agoRUBYRubius Therapeutics to Participate in Jefferies London Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cel
- 5y agoRUBYRubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireU.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius' Third Oncology CandidateClinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumor
- 5y agoAXLACDAKDNLIEVLO+8Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship's Pioneering Medicines to Treat Cystic FibrosisBusiness WireTessera's Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their Entirety Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundatio
- 5y agoRUBYRubius Therapeutics to Announce Third Quarter 2021 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Ce
- 5y agoAXLACDAKDNLIEVLO+7Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate ChangePR NewswireCAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into
- 5y agoRUBYRubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer's Annual MeetingGlobeNewswireCAMBRIDGE Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell